The FDA has issued a safety communication recommending that certain patients stop taking Allergan’s Viberzi, and for healthcare professionals to stop prescribing it to certain populations immediately.
Viberzi is supposed to help those with irritable bowel syndrome with diarrhea, or IBS-D, by decreasing bowel contractions, easing pain, and improving stool consistency.
Viberzi poses the most risk to individuals without a gallbladder. The FDA has received at least 120 ...
continue reading...